BioSpace News Archive

Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that topline data from a Phase 1b placebo-controlled, multiple ascending dose clinical study showed that BIIB080/IONIS-MAPTRx met its primary objective of safety and tolerability in patients with mild Alzheimer’s disease.

Race, in combination with other factors, predicted how quickly individuals with stroke got to stroke centers to receive necessary neuroendovascular stroke surgery, according to research presented at the Society of NeuroInterventional Surgery’s 18th Annual Meeting.

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced an equity inducement grant to one new employee consisting of an aggregate of 15,000 stock options.

ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that Dr. Revati Shreeniwas has joined the company as Chief Medical Officer.

Kiromic Biopharma, Inc. (Nasdaq: KRBP), a pioneer in immuno oncology cellular therapy in solid tumors, is pleased to announce it has completed the acquisition of InSilico Solutions.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and GC Pharma (KRX:006280) today announced that they have entered into an exclusive licensing agreement, pursuant to which GC Pharma has agreed to develop and commercialize maralixibat in South Korea.

Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the pricing of its initial public offering of 9,000,000 shares of common stock at a public offering price of $8.00 per share.

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics’ CRISPR/Cas9 patent portfolio.